Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alogliptin + Actoplus Met in T2DM with MAFLD
NCT07289750Phase 4Not yet recruiting
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- Start
- May 2026
- Primary completion
- Aug 2027
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of alogliptin in type 2 diabetes mellitus (T2DM), metabolic dysfunction associated fatty liver disease (MAFLD), sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine. Planned start May 2026; status: not yet recruiting.
02
Drugs
alogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic dysfunction associated fatty liver disease (MAFLD)
Beyond the preview
Go deeper on NCT07289750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07289750.